News and Announcements
Yale Hematolgy Leader Joins Prescient Therapeutics Scientific Advisory Board
- Published January 14, 2016 11:19AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
14th January 2016, ASX Announcement
Clinical stage oncology company Prescient Therapeutics Ltd (PTX) has appointed a highly respected US-based specialist in myeloid malignancies Dr Thomas Prebet MD, PhD of Yale Cancer Center to the PTX Scientific Advisory Board (SAB).
Dr Prebet is the Assistant Director of Myeloid Malignancy Research at Yale, where he is looking to expand the clinical and translational research program in myeloid malignancies.
Dr Prebet was previously with the Insitiut Paoli-Calmettes in Marseille France where he was an Associate Professor of Clinical Hematology and a member of the molecular pharmacology group, as well as the early phase trial group and coordiniator of the leukemia ward.
To read the full announcement, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
